압타머 시장 규모 : 유형, 용도, 기술, 최종 용도별, 세계 예측(2023-2032년)

Aptamers Market size is estimated to grow at more than 20% CAGR from 2023 to 2032, driven by the rising prevalence of chronic diseases coupled with the surging need for targeted therapies and personalized medicine solutions. Aptamers, with their high specificity and affinity for various disease targets, are gaining traction as viable alternatives to conventional treatment modalities. Owing to their potential for precise and efficient drug delivery along with minimal off-target effects and reduced immunogenicity, aptamers are matching the growing demand for personalized medicine solutions.

Moreover, industry players are investing in R&D activities for the advancement of aptamer technology. For instance, in October 2023, Zentek Ltd. partnered with McMaster University to launch a fully owned subsidiary that would own the exclusive, international licensing rights for all aptamer-based technology.

The overall aptamers market is segmented into type, application, technology, end-use, and region.

Based on type, the RNA-based aptamers industry is set to gain significant traction from 2023-2032. With their unique ability to bind to wide range of target molecules, RNA-based aptamers have garnered significant attention in the field of therapeutics, diagnostics, and research applications. Moreover, the rising advancements in RNA aptamer selection techniques, including modified SELEX methodologies and the ongoing R&D activities to explore the potential applications of RND-based aptamers will propel the segment growth. For instance, in September 2023, the FDA authorized Iveric Bio/Astellas' avacincaptad pegol for geographic atrophy secondary to treat age-associated macular degeneration.

In terms of application, the aptamers market size from the diagnostics segment is expected to record robust growth through 2032. Owing to their rapid and sensitive detection capabilities along with higher potential for multiplexing and cost-effective production, aptamers have emerged as valuable tools in the development of diagnostic assays. With the upsurge in demand for accurate and efficient diagnostic solutions across various healthcare settings and advancements, the segment is poised to record considerable growth.

Regionally, the Asia Pacific aptamers industry recorded robust proceeds in 2022 and is expected to foresee significant growth fueled by the increasing focus on biotechnological R&D activities, particularly in China, Japan, and India. The rising prevalence of chronic diseases coupled with the presence of large and aging population is bolstering the demand for effective and targeted therapeutic solutions in the region, further driving the adoption of aptamers. Additionally, government initiatives for promoting the development of the biopharmaceutical sector coupled with increasing collaboration between academic research institutions and industry players will propel the market growth.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market definition
• 1.2 Base estimates & calculations
• 1.3 Forecast parameters
• 1.4 COVID-19 impact analysis at global level
• 1.5 Data validation
• 1.6 Data Sources
  • 1.6.1 Primary
  • 1.6.2 Secondary
    • 1.6.2.1 Paid sources
    • 1.6.2.2 Public sources

Chapter 2 Executive Summary

• 2.1 Aptamers industry 360 degree synopsis, 2018 - 2032
  • 2.1.1 Business trends
  • 2.1.2 Regional trends
  • 2.1.3 Type trends
  • 2.1.4 Application trends
  • 2.1.5 Technology trends
  • 2.1.6 End-use trends

Chapter 3 Aptamers Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 High advantage of aptamers compared to antibodies
    • 3.2.1.2 Increasing investments in pharmaceutical R&D
    • 3.2.1.3 Rising number of clinical trials to develop aptamer-based therapeutics
    • 3.2.1.4 Increasing prevalence of chronic and rare diseases
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Growing instances of late-stage clinical study setbacks for aptamer therapeutics
    • 3.2.2.2 Low awareness level and incomplete regulatory policies
• 3.3 Growth potential analysis
  • 3.3.1 By type
  • 3.3.2 By application
  • 3.3.3 By technology
  • 3.3.4 By end-use
• 3.4 COVID- 19 impact analysis
• 3.5 Regulatory landscape
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2022

• 4.1 Introduction
• 4.2 Company matrix analysis, 2022
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Aptamers Market, By Type, 2018 - 2032 (USD Million)

• 5.1 Key trends, by type
• 5.2 DNA-based aptamers
• 5.3 RNA-based aptamers
• 5.4 XNA-based aptamers

Chapter 6 Aptamers Market, By Application, 2018 - 2032 (USD Million)

• 6.1 Key trends, by application
• 6.2 Research & development
• 6.3 Diagnostics
• 6.4 Therapeutics
• 6.5 Other applications

Chapter 7 Aptamers Market, By Technology, 2018 - 2032 (USD Million)

• 7.1 Key trends, by technology
• 7.2 SELEX
• 7.3 X-aptamers
• 7.4 Other technologies

Chapter 8 Aptamers Market, By End-use, 2018 - 2032 (USD Million)

• 8.1 Key trends, by end-use
• 8.2 Pharmaceutical & biotechnology companies
• 8.3 Academic & government research institutes
• 8.4 CROs
• 8.5 Other end-users

Chapter 9 Aptamers Market, By Region, 2018 - 2032 (USD Million)

• 9.1 Key trends, by region
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Rest of Latin America
• 9.6 Middle East & Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 Rest of Middle East & Africa

Chapter 10 Company Profiles

• 10.1 SomaLogic
• 10.2 Aptamer Group
• 10.3 Aptadel Therapeutics
• 10.4 Base Pair Biotechnologies
• 10.5 Vivonics Inc.
• 10.6 Aptagen, LLC
• 10.7 TriLink Biotechnologies
• 10.8 Aptus Biotech
• 10.9 Novaptech
• 10.10 NeoVentures Biotechnology Inc.